Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal treatments, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 9:10 am EDT and the H.C. Wainwright Global Investment Conference on September 8 at 1:00 pm EDT.
Phathom's management team will conduct one-on-one meetings during both conferences. The company currently markets VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT), azienda biofarmaceutica specializzata in terapie gastrointestinali, ha annunciato la partecipazione a due conferenze per investitori previste per settembre 2025. La società terrà una presentazione al Cantor Global Healthcare Conference il 3 settembre alle 9:10 EDT e al H.C. Wainwright Global Investment Conference l'8 settembre alle 13:00 EDT.
Il team di gestione di Phathom effettuerà incontri one-to-one durante entrambe le conferenze. L'azienda commercializza attualmente VOQUEZNA®, un inibitore competitivo del potassio di prima classe (PCAB) per diverse patologie gastrointestinali, tra cui la RGE non erosiva e il trattamento delle infezioni da H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT), una compañía biofarmacéutica especializada en tratamientos gastrointestinales, ha anunciado su participación en dos conferencias para inversores en septiembre de 2025. La empresa presentará en el Cantor Global Healthcare Conference el 3 de septiembre a las 9:10 EDT y en el H.C. Wainwright Global Investment Conference el 8 de septiembre a la 1:00 pm EDT.
El equipo directivo de Phathom mantendrá reuniones individuales durante ambas conferencias. La compañía comercializa actualmente VOQUEZNA®, un inhibidor competitivo de potasio de primera clase (PCAB) para diversas afecciones gastrointestinales, incluyendo la ERGE no erosiva y el tratamiento de la infección por H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT), 위장 질환 치료를 전문으로 하는 바이오제약 회사가 2025년 9월에 열리는 두 건의 투자자 컨퍼런스에 참가한다고 발표했습니다. 회사는 Cantor Global Healthcare Conference에서 9월 3일 오전 9시 10분(EDT)에, H.C. Wainwright Global Investment Conference에서는 9월 8일 오후 1시(EDT)에 발표를 진행합니다.
Phathom의 경영진은 두 컨퍼런스 기간 동안 일대일 미팅을 실시할 예정입니다. 회사는 현재 다양한 위장 질환에 사용되는 1세대 칼륨경쟁성 산분비억제제(PCAB)인 VOQUEZNA®를 판매하고 있으며, 비침식성 위식도역류질환(Non-Erosive GERD) 및 H. pylori 감염 치료 등에 적응증을 가지고 있습니다.
Phathom Pharmaceuticals (NASDAQ: PHAT), une entreprise biopharmaceutique spécialisée dans les traitements gastro-intestinaux, a annoncé sa participation à deux conférences investisseurs prévues en septembre 2025. La société présentera au Cantor Global Healthcare Conference le 3 septembre à 9h10 EDT et au H.C. Wainwright Global Investment Conference le 8 septembre à 13h00 EDT.
L'équipe de direction de Phathom tiendra des réunions individuelles lors des deux conférences. La société commercialise actuellement VOQUEZNA®, un inhibiteur compétitif du potassium de première génération (PCAB) pour diverses affections gastro-intestinales, y compris le RGO non érosif et le traitement des infections à H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT), ein biopharmazeutisches Unternehmen, das sich auf gastrointestinale Therapien spezialisiert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird am Cantor Global Healthcare Conference am 3. September um 9:10 Uhr EDT und am H.C. Wainwright Global Investment Conference am 8. September um 13:00 Uhr EDT präsentieren.
Das Managementteam von Phathom wird während beider Konferenzen Einzelgespräche führen. Das Unternehmen vertreibt derzeit VOQUEZNA®, einen erstklassigen kaliumkompetitiven Säurehemmer (PCAB) für verschiedene gastrointestinale Erkrankungen, einschließlich nicht-erosiver GERD und der Behandlung von H.-pylori-Infektionen.
- None.
- None.
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
Cantor Global Healthcare Conference 2025 in New York, NY
Date: Wednesday, September 3, 2025
Live Webcast: 9:10 am EDT
Management to participate in 1x1 meetings throughout the conference, which runs September 3-5, 2025.
H.C. Wainwright 27th Annual Global Investment Conference in New York, NY
Date: Monday, September 8, 2025
Live Webcast: 1:00 pm EDT
Management to participate in 1x1 meetings throughout the conference, which runs September 8-10, 2025.
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for up to 90 days following the conclusion of each webcast.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When is Phathom Pharmaceuticals (PHAT) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Phathom Pharmaceuticals' (PHAT) conference presentations?
What products does Phathom Pharmaceuticals (PHAT) currently market?
When is Phathom Pharmaceuticals (PHAT) presenting at the H.C. Wainwright Conference?
